Although defining subtypes by ER, PR, and HER2 expression does not entirely approximate results of genomic profiling, this classification offers a practical substitute that is increasingly well characterized in published literature [5,7-9,40-42] and that guides breast cancer treatment [43]. The gene discussed is ERBB2; the disease is breast cancer.